Biotech's Bright Spot: What Alnylam's Record Quarter Reveals About RNA Interference The biotech sector has seen its share of boom and bust cycles, but 2026 appears to be a year of sustained growth.
Venture funding, IPOs, and dealmaking are all on the rise, yet one company stands out: Alnylam Pharmaceuticals. Its Q1 results are remarkable – $1. 036 billion in net product revenue, a 121% year over year increase.
However, the market's muted response to this success is striking. Alnylam's performance validates the growing importance of RNA interference (RNAi) in treating rare diseases.